Checkpoint Capital L.P. Has $3.74 Million Stock Position in Kymera Therapeutics, Inc. $KYMR

Key Points

• Checkpoint Capital L.P. increased its stake in Kymera Therapeutics by 76.2%, owning approximately $3.74 million worth of shares.
• Several institutional investors, including Wellington Management and Vanguard Group, also raised their positions, indicating strong interest in Kymera Therapeutics.
• Kymera reported a wider-than-expected loss of ($0.95) earnings per share, with revenue down 55.1% from the previous year, leading to a consensus forecast of -2.79 EPS for the current fiscal year.

Checkpoint Capital L.P. raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 76.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 136,605 shares of the company's stock after acquiring an additional 59,070 shares during the period. Kymera Therapeutics makes up approximately 2.1% of Checkpoint Capital L.P.'s investment portfolio, making the stock its 9th largest position. Checkpoint Capital L.P. owned about 0.21% of Kymera Therapeutics worth $3,739,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in KYMR. Wellington Management Group LLP boosted its holdings in shares of Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after acquiring an additional 689,547 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics during the fourth quarter worth approximately $23,856,000. Janus Henderson Group PLC boosted its holdings in shares of Kymera Therapeutics by 2,397.9% during the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company's stock worth $15,197,000 after acquiring an additional 362,276 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after acquiring an additional 344,080 shares during the period. Finally, Siren L.L.C. raised its position in shares of Kymera Therapeutics by 9.1% in the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company's stock valued at $88,687,000 after buying an additional 270,580 shares in the last quarter.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $43.30 on Thursday. The company has a fifty day moving average of $43.46 and a 200-day moving average of $36.91. The company has a market capitalization of $3.10 billion, a PE ratio of -12.48 and a beta of 2.17. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same period in the prior year, the firm earned ($0.58) EPS. The business's revenue for the quarter was down 55.1% compared to the same quarter last year. On average, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KYMR has been the subject of a number of analyst reports. Guggenheim reiterated a "buy" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $70.00 price target for the company. Oppenheimer reiterated an "outperform" rating and issued a $53.00 price target (down from $56.00) on shares of Kymera Therapeutics in a research report on Friday, June 27th. B. Riley upgraded shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price target for the company in a research report on Wednesday, July 30th. Finally, The Goldman Sachs Group upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $58.76.

Insider Activity at Kymera Therapeutics

In other news, Director Bvf Partners L. P/Il purchased 317,167 shares of the stock in a transaction on Monday, June 30th. The stock was purchased at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the acquisition, the director owned 2,798,795 shares in the company, valued at $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of the business's stock in a transaction on Monday, June 30th. The shares were purchased at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the transaction, the director directly owned 6,117,295 shares of the company's stock, valued at approximately $269,160,980. The trade was a 12.00% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.